Overview

The COVID-19 data platform is founded upon collaborations with ISARIC, the COVID-19 Clinical Research Coalition, the ANTICOV trial platform, CDRC, CDISC and the wider research community. The work is co-ordinated by a team based at IDDO.

COVID-19 is an emerging infectious disease caused by a new coronavirus called SARS-CoV-2. As a novel disease, there is limited understanding of this, how it impacts people differently, and how to treat it effectively. IDDO works with the research community to address these questions as quickly as possible through the activities below.

Scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab
i
Credit: NIAID-RML

COVID-19 clinical data platform

In collaboration with ISARIC (the International Severe Acute Respiratory and emerging Infections Consortium) IDDO has developed a COVID-19 clinical data platform with a governance and ethical framework to ensure the equitable sharing of data. The platform’s infrastructure includes a secure web environment for submissions, a repository where diverse data are harmonised and stored, and an open inventory of hosted data to ensure their long-term security and accessibility.

Extensive global uptake of this resource has resulted in the world’s largest standardised collection of comprehensive clinical data, these are analysed regularly and reported publicly to inform patient care and the public health response.

COVID-19 living systematic review (LSR) of registered clinical trials

The LSR is an open, accessible and frequently updated resource summarising the characteristics of COVID-19 clinical trial registry records. The LSR is created by curating the WHO International Clinical Trials Registry Platform (ICTRP) database and by extracting complementary information from source clinical trial registries. In partnership with Exaptive, a searchable and interactive visualisation of the results database is available online.

COVID-19 medical product quality reports

IDDO’s Medicine Quality Research Group is monitoring and analysing information in the public domain pertaining to the quality   of COVID-19 medical products, including medicines, vaccines and equipment during the response and produces monthly medical product quality reports. Its global tool tracks news reports of substandard and falsified medical products in real-time and includes reports on COVID-19.

COVID-19 CDISC data standards

IDDO is part of the task force established by CDISC to rapidly develop an interim COVID-19 Therapeutic Area User Guide to standardise clinical data. The guide details how data fields specific to COVID-19 will be incorporated into the CDISC standards. CDISC has also developed an annotated case record form and mapping tool to support researchers to collect high-quality data in a format that enables integration with other datasets. The tools are freely available on the CDISC website (requires free registration).

 

IDDO is registered as a re3data.org repository. To stay informed with the development of the COVID-19 data platform sign up to our newsletter and for further information please contact us at: info@iddo.org